The estimated Net Worth of Jacqualyn A Fouse is at least $22.8 Million dollars as of 13 June 2024. Jacqualyn Fouse owns over 3,388 units of Agios Pharmaceuticals Inc stock worth over $6,238,139 and over the last 17 years he sold AGIO stock worth over $0. In addition, he makes $16,608,000 as Chief Executive Officer und Director at Agios Pharmaceuticals Inc.
Jacqualyn has made over 40 trades of the Agios Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,388 units of AGIO stock worth $150,122 on 13 June 2024.
The largest trade he's ever made was buying 40,322 units of Agios Pharmaceuticals Inc stock on 13 November 2019 worth over $1,249,982. On average, Jacqualyn trades about 2,125 units every 27 days since 2007. As of 13 June 2024 he still owns at least 140,784 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Jacqualyn Fouse stock trades at the bottom of the page.
Dr. Jacqualyn A. Fouse Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Fouse served as executive chair of Dermavant Sciences, a biopharmaceutical company, from July 2017 until September 2018. From September 2010 until June 2017, Dr. Fouse served in various capacities at Celgene Corporation, a biopharmaceutical company, or Celgene, serving as strategic advisor to the management executive committee from April 2017 to June 2017, president and chief operating officer from March 2016 to March 2017, president, hematology and oncology from August 2014 to February 2016, executive vice president and chief financial officer from February 2012 to July 2014, and senior vice president and chief financial officer from September 2010 to February 2012. Prior to joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, or Bunge, a global agribusiness and food company, from 2007 to 2010. Prior to joining Bunge, Dr. Fouse served as senior vice president, chief financial officer and corporate strategy at Alcon Laboratories, Inc., or Alcon, a global medical company, since 2006, and as its senior vice president and chief financial officer since 2002. Prior to her time with Alcon she held a variety of senior leadership roles with international companies. Dr. Fouse is also a director and member of the audit committee of Incyte and is a director and member of the audit committee of Dick’s Sporting Goods, Inc., a public sporting goods retailer, and was a director of Perrigo Company from November 2012 to April 2016 and a director of Celgene from February 2016 until June 2017. Dr. Fouse has informed us that she will not be standing for reelection to the board of directors of Dick’s Sporting Goods, Inc. at its upcoming annual meeting in June 2020. Dr. Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington. She also earned a Masters in Environmental Management from the Yale University School of Forestry and Environmental Studies.
As the Chief Executive Officer und Director of Agios Pharmaceuticals Inc, the total compensation of Jacqualyn Fouse at Agios Pharmaceuticals Inc is $16,608,000. There are no executives at Agios Pharmaceuticals Inc getting paid more.
Jacqualyn Fouse is 58, he's been the Chief Executive Officer und Director of Agios Pharmaceuticals Inc since 2019. There are 13 older and 7 younger executives at Agios Pharmaceuticals Inc. The oldest executive at Agios Pharmaceuticals Inc is Dr. Tak Wah Mak, 75, who is the Co-Founder & Member of Scientific Advisory Board.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen und John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: